Yuen Maggie
Known title: DirectorCIK: 0001796057
Associated companies
Transaction History
| ATRC | ▼ Sell | Open Market | 3,500 | $134K | 8/5/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 6,144 | $0 | 5/18/2026 | View on chart |
| ATRC | ▼ Sell | Open Market | 3,000 | $107K | 11/21/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 5,401 | $0 | 5/19/2025 | View on chart |
| ATRC | ▼ Sell | Open Market | 3,500 | $84K | 8/15/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 7,788 | $0 | 5/13/2024 | View on chart |
| ATRC | ▼ Sell | Open Market | 4,313 | $203K | 5/26/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 3,186 | $0 | 5/25/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 3,564 | $0 | 5/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BTIG raises AtriCure price target to $63
BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.
BTIG raises AtriCure price target to $63. BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.